From the Department of Neurosurgery, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
The Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
Brain Behav Immun. 2019 Nov;82:13-24. doi: 10.1016/j.bbi.2019.07.027. Epub 2019 Jul 26.
White matter damage is an important contributor to long-term neurological deficit after stroke. Our previous study has shown that inhibition of CD147 ameliorates acute ischemic stroke in mice. In this study, we aimed to investigate whether inhibition of CD147 promotes white matter repair and long-term functional recovery after ischemic stroke.Male adult C57BL/6 mice were subjected to transient (1-h) middle cerebral artery occlusion (tMCAO). Anti-CD147 function-blocking antibody (αCD147) was injected intravenously once daily for 3 days beginning 4 h after onset of ischemia. Sensorimotor and cognitive functions were evaluated up to 28 days after stroke. We found that αCD147 treatment not only prevented neuronal and oligodendrocyte cell death in the acute phase, but also profoundly protected white matter integrity and reduced brain atrophy and tissue loss in the late phase, leading to improved sensorimotor and cognitive functions for at least 28 days after stroke. Mechanistically, we found that αCD147 treatment increased the number of proliferating NG2(+)/PDGFRα(+) oligodendrocyte precursor cells (OPCs) and newly generated mature APC(+)/Sox10(+) oligodendrocytes after stroke, possibly through upregulation of SDF-1/CXCR4 axis in OPCs. In conclusion, inhibition of CD147 promotes long-term functional recovery after stroke, at least in part, by enhancing oligodendrogenesis and white matter repair.
脑白质损伤是中风后长期神经功能缺损的重要原因。我们之前的研究表明,抑制 CD147 可改善小鼠急性缺血性中风。在这项研究中,我们旨在探讨抑制 CD147 是否能促进缺血性中风后的白质修复和长期功能恢复。
雄性成年 C57BL/6 小鼠接受短暂(1 小时)大脑中动脉闭塞(tMCAO)。在缺血后 4 小时开始,每天静脉注射一次抗 CD147 功能阻断抗体(αCD147),持续 3 天。中风后最多 28 天评估感觉运动和认知功能。我们发现,αCD147 治疗不仅在急性期预防神经元和少突胶质细胞死亡,而且在晚期还能显著保护白质完整性,减少脑萎缩和组织丢失,从而改善中风后至少 28 天的感觉运动和认知功能。
从机制上讲,我们发现αCD147 治疗增加了中风后增殖的 NG2(+)/PDGFRα(+)少突胶质前体细胞(OPC)和新生成的成熟 APC(+)/Sox10(+)少突胶质细胞的数量,可能是通过 OPC 中 SDF-1/CXCR4 轴的上调。
总之,抑制 CD147 可通过增强少突胶质细胞发生和白质修复,促进中风后的长期功能恢复。